Physician profile
Amanda E Deal
NPI 1750776126
$2,103.46
in general payments reported to CMS, 2019-2025
20 companies · $1,188 in 2025
The $1,188 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $64.29 · 2022: $60.51 · 2023: $59.09 · 2024: $732 · 2025: $1,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,978.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $489.75 | 2021-2025 | Ubrelvy |
| Novo Nordisk INC | $314.58 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $181.15 | 2024-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $157.77 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $153.44 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $136.53 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $97.43 | 2021-2025 | |
| Axsome Therapeutics, INC. | $94.46 | 2024-2025 | Auvelity |
| Pfizer INC. | $88.67 | 2024-2025 | |
| Exact Sciences Corporation | $78.97 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $62.12 | 2024-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $47.03 | 2024 | Quviviq |
| Abbott Laboratories | $46.07 | 2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $45.25 | 2024-2025 | Veozah |
| Scilex Pharmaceuticals INC. | $31.09 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.50 | 2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $17.29 | 2025 | Austedo Xr |
| Harmony Biosciences LLC | $16.78 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $13.94 | 2025 | Zoryve |
| Phathom Pharmaceuticals, INC. | $13.64 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Deal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.